22Purpose: To compare corneal biomechanics between patients with ocular graft versus-host 23 disease (oGVHD) and healthy subjects (controls), and to further correlate these values with 24 ocular and hematological characteristics. 25 Materials and Methods: The following procedures were performed in oGVHD patients and 26 controls: Schirmer test (ST), break-up time (BUT), corneal and conjunctival staining, tear 27 matrix metalloproteinase-9 (MMP-9) assay (InflammaDry test, Rapid Pathogen Screening, 28 Inc, Sarasota, FL). Corneal biomechanics were calculated by using ocular response analyzer 29 (ORA, Reichert Instruments, Depew, New York, USA). The Mann-Whitney U test was used 30 to compare continuous variables between oGVHD patients and controls. Correlations of 31 corneal biomechanics with ocular and hematological parameters were examined using 32Spearman's correlation.
33Results: A total of 45 oGVHD patients (mean age ± SD, 51.5 ± 7.1 years) and 34 controls 34 (47.8 ± 6.1 years) were included. Patients with oGVHD showed significantly lower values of 35 corneal hysteresis (CH) and corneal resistance factor (CRF) compared to controls 36 (respectively, 9.4 ± 1.8 mmHg vs 11.6 ± 1.6 and 9.7 ± 1.4 mmHg vs 12.3 ± 1.3; always 37 p<0.001). Twenty-nine of the oGVHD eyes (64.4%) were strong-positive for MMP-9, while 38 16 (35.6%) were weak-positive. Conversely, only 4 of the control eyes (11.8%) were weak-39 positive for MMP-9. In patients with oGVHD, CH was significantly correlated with corneal 40 staining (Rs = -0.316, p = 0.035), conjunctival staining (Rs = -0.437, p = 0.003), ST (Rs = 41 0.390, p = 0.008), BUT (Rs = 0.423, p = 0.004), oGVHD severity grade (Rs = -0.383, p = 42 0.009), and MMP-9 positivity grade (Rs = -0.429, p = 0.003), while CRF was correlated only 43 with corneal staining (Rs = -0.317, p = 0.034).
44Conclusions: Corneal biomechanics are reduced in patients with oGVHD, and CH is 45 negatively correlated with disease severity grade and MMP-9 tear levels. 46 47 51 Allogeneic hematopoietic stem cell transplantation (HSCT) is an established and potentially 52 curative treatment for a variety of malignant and non-malignant hematological disorders. 53 Graft versus-host disease (GVHD) is a multi-organ systemic disease caused by complex 54 interactions between donor and recipient immune systems and represents the leading cause of 55 morbidity following HSCT.[1] Chronic ocular GVHD (oGVHD) develops in 40 to 60% of 56 patients undergoing HSCT, and dry eye disease (DED) represents the hallmark of this 57 condition.[2-4] The disease is thought to be the result of the progressive immune-mediate 58 inflammatory damage of ocular surface structures, which may lead to lacrimal and meibomian 59 glands dysfunction, conjunctival keratinization, corneal epitheliopathy, eyelid laxity and 60 scarring, and in more severe cases even corneal melting and perforation.[5-7] 61 Recent proteomic studies evaluated the various constituent compositions of tears 62 inflammatory mediators in eyes with oGVHD and detected increased levels of...